Switch theme
Sign up to access all valuation multiples
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
2000
29
LTM Revenue $7.3M
LTM EBITDA -$27.8M
$159M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vicore Pharma Holding has a last 12-month revenue (LTM) of $7.3M and a last 12-month EBITDA of -$27.8M.
In the most recent fiscal year, Vicore Pharma Holding achieved revenue of $11.4M and an EBITDA of -$17.4M.
Vicore Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vicore Pharma Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.3M | XXX | $11.4M | XXX | XXX | XXX |
| Gross Profit | -$24.9M | XXX | $11.4M | XXX | XXX | XXX |
| Gross Margin | -341% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$27.8M | XXX | -$17.4M | XXX | XXX | XXX |
| EBITDA Margin | -382% | XXX | -152% | XXX | XXX | XXX |
| EBIT | -$36.9M | XXX | -$19.9M | XXX | XXX | XXX |
| EBIT Margin | -507% | XXX | -174% | XXX | XXX | XXX |
| Net Profit | -$26.6M | XXX | -$17.6M | XXX | XXX | XXX |
| Net Margin | -365% | XXX | -154% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 14, 2025, Vicore Pharma Holding's stock price is SEK 8 (or $1).
Vicore Pharma Holding has current market cap of SEK 1.8B (or $187M), and EV of SEK 1.5B (or $159M).
See Vicore Pharma Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $159M | $187M | XXX | XXX | XXX | XXX | $-0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 14, 2025, Vicore Pharma Holding has market cap of $187M and EV of $159M.
Vicore Pharma Holding's trades at 13.9x EV/Revenue multiple, and -9.1x EV/EBITDA.
Equity research analysts estimate Vicore Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vicore Pharma Holding has a P/E ratio of -7.0x.
See valuation multiples for Vicore Pharma Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $187M | XXX | $187M | XXX | XXX | XXX |
| EV (current) | $159M | XXX | $159M | XXX | XXX | XXX |
| EV/Revenue | 21.9x | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBITDA | -5.7x | XXX | -9.1x | XXX | XXX | XXX |
| EV/EBIT | -4.3x | XXX | -8.0x | XXX | XXX | XXX |
| EV/Gross Profit | -6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.0x | XXX | -10.6x | XXX | XXX | XXX |
| EV/FCF | -7.2x | XXX | -9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVicore Pharma Holding's last 12 month revenue growth is -43%
Vicore Pharma Holding's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.1M for the same period.
Vicore Pharma Holding's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vicore Pharma Holding's rule of X is -489% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vicore Pharma Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -43% | XXX | -38% | XXX | XXX | XXX |
| EBITDA Margin | -382% | XXX | -152% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -195% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -489% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 228% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 274% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vicore Pharma Holding acquired XXX companies to date.
Last acquisition by Vicore Pharma Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Vicore Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vicore Pharma Holding founded? | Vicore Pharma Holding was founded in 2000. |
| Where is Vicore Pharma Holding headquartered? | Vicore Pharma Holding is headquartered in Sweden. |
| How many employees does Vicore Pharma Holding have? | As of today, Vicore Pharma Holding has 29 employees. |
| Who is the CEO of Vicore Pharma Holding? | Vicore Pharma Holding's CEO is Mr. Ahmed Mousa. |
| Is Vicore Pharma Holding publicy listed? | Yes, Vicore Pharma Holding is a public company listed on STO. |
| What is the stock symbol of Vicore Pharma Holding? | Vicore Pharma Holding trades under VICO ticker. |
| When did Vicore Pharma Holding go public? | Vicore Pharma Holding went public in 2015. |
| Who are competitors of Vicore Pharma Holding? | Similar companies to Vicore Pharma Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vicore Pharma Holding? | Vicore Pharma Holding's current market cap is $187M |
| What is the current revenue of Vicore Pharma Holding? | Vicore Pharma Holding's last 12 months revenue is $7.3M. |
| What is the current revenue growth of Vicore Pharma Holding? | Vicore Pharma Holding revenue growth (NTM/LTM) is -43%. |
| What is the current EV/Revenue multiple of Vicore Pharma Holding? | Current revenue multiple of Vicore Pharma Holding is 21.9x. |
| Is Vicore Pharma Holding profitable? | Yes, Vicore Pharma Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vicore Pharma Holding? | Vicore Pharma Holding's last 12 months EBITDA is -$27.8M. |
| What is Vicore Pharma Holding's EBITDA margin? | Vicore Pharma Holding's last 12 months EBITDA margin is -382%. |
| What is the current EV/EBITDA multiple of Vicore Pharma Holding? | Current EBITDA multiple of Vicore Pharma Holding is -5.7x. |
| What is the current FCF of Vicore Pharma Holding? | Vicore Pharma Holding's last 12 months FCF is -$22.2M. |
| What is Vicore Pharma Holding's FCF margin? | Vicore Pharma Holding's last 12 months FCF margin is -305%. |
| What is the current EV/FCF multiple of Vicore Pharma Holding? | Current FCF multiple of Vicore Pharma Holding is -7.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
